抑制CD226共刺激通过增强调节性T细胞和削弱效应T细胞功能抑制NOD小鼠糖尿病发生
在雌性NOD小鼠7-8周龄给予抗CD226单克隆抗体,12周时胰岛炎严重程度降低0.84倍(p=0.0002),30周时糖尿病发病率降低(HR 0.41,p=0.015)。机制上抗CD226减少常规CD4+和CD8+效应记忆T细胞增殖,增强胰腺Treg的CD25表达和STAT5磷酸化,并降低胰岛特异性CD8+ T细胞频率及对β细胞的细胞毒性。
要点
- 抗CD226降低NOD小鼠12周胰岛炎严重程度0.84倍(p=0.0002)和30周糖尿病发病率(HR 0.41,p=0.015)。
- 抗CD226增强Treg功能:胰腺Treg CD25表达增加2.05倍(p=0.0073),STAT5磷酸化增加1.39倍(p=0.0007)。
- 抗CD226削弱效应T细胞:脾CD4+和CD8+效应记忆T细胞增殖降低,β细胞裂解减少0.61倍(p<0.0001)。
核心结论
- CD226阻断降低T细胞细胞毒性并改善Treg功能,代表一种恢复1型糖尿病免疫调节的靶向合理方法。
研究设计与样本
- 雌性NOD小鼠在7-8周龄接受抗CD226治疗,随后监测糖尿病发病率和治疗作用机制。
主要发现
- 与同型对照相比,抗CD226治疗的NOD小鼠12周时胰岛炎严重程度降低0.84倍(p=0.0002),30周时糖尿病发病率降低(HR 0.41,p=0.015)。
- 治疗后5周流式细胞术显示,抗CD226治疗小鼠脾脏中常规CD4+ T细胞增殖降低0.87倍(p=0.030),CD8+效应记忆T细胞增殖降低0.78倍(p=0.0018)。
- 胰腺Treg表型显示抗CD226后CD25表达增加2.05倍(p=0.0073),STAT5磷酸化增加1.39倍(p=0.0007);脾Treg在体外对CD4+应答T细胞的抑制增强1.49倍(p=0.0008,Treg:Tresp 1:2)。
- 抗CD226治疗小鼠胰腺中胰岛特异性葡萄糖-6-磷酸酶催化亚基相关蛋白(IGRP)反应性CD8+ T细胞频率降低,离体四聚体染色降低0.50倍(p=0.0317),单细胞T细胞受体测序降低0.61倍(p=0.022)。
- 51Cr释放实验显示抗CD226治疗的自反应性细胞毒性T淋巴细胞对β细胞的裂解降低0.61倍(p<0.0001,效应:靶标 1:1)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Immunotherapeutics targeting T cells are crucial for inhibiting autoimmune disease progression proximal to disease onset in type 1 diabetes. There is an outstanding need to augment the durability and effectiveness of T cell targeting therapies by directly restraining proinflammatory T cell subsets, while simultaneously augmenting regulatory T cell (Treg) activity. Here, we present a novel strategy for preventing diabetes incidence in the NOD mouse model using a blocking monoclonal antibody targeting the type 1 diabetes risk-associated T cell co-stimulatory receptor, CD226. METHODS: Female NOD mice were treated with anti-CD226 at 7-8 weeks of age and then monitored for diabetes incidence and therapeutic mechanism of action. RESULTS: Compared with isotype-treated controls, anti-CD226-treated NOD mice showed reduced insulitis severity (0.84-fold, p=0.0002) at 12 weeks and decreased disease incidence (HR 0.41, p=0.015) at 30 weeks. Flow cytometric analysis performed 5 weeks post treatment demonstrated reduced proliferation of conventional CD4+ T cells (0.87-fold, p=0.030) and CD8+ (0.78-fold, p=0.0018) effector memory T cells in spleens of anti-CD226-treated mice. Phenotyping of pancreatic Tregs revealed increased CD25 expression (2.05-fold, p=0.0073) and signal transducer and activator of transcription 5 (STAT5) phosphorylation (1.39-fold, p=0.0007) following anti-CD226, with splenic Tregs displaying augmented suppression of CD4+ responder T cells (Tresps) (1.49-fold, p=0.0008, 1:2 Treg:Tresp) in vitro. Anti-CD226-treated mice exhibited reduced frequencies of islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP)-reactive CD8+ T cells in the pancreas, using both ex vivo tetramer staining (0.50-fold, p=0.0317) and single-cell T cell receptor sequencing (0.61-fold, p=0.022) approaches. 51Cr-release assays demonstrated reduced cell-mediated lysis of beta cells (0.61-fold, p<0.0001, 1:1 effector:target) by anti-CD226-treated autoreactive cytotoxic T lymphocytes. CONCLUSIONS/INTERPRETATION: CD226 blockade reduces T cell cytotoxicity and improves Treg function, representing a targeted and rational approach for restoring immune regulation in type 1 diabetes.
引用
- Brown ME, Thirawatananond P, Peters LD, et al. Inhibition of CD226 co-stimulation suppresses diabetes development in the NOD mouse by augmenting regulatory T cells and diminishing effector T cell function. Diabetologia. 2024. PMID: 39636437. doi:10.1007/s00125-024-06329-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。